Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features.
Adult patient with Epstein-Barr virus (EBV)-associated lymphoproliferative disorder: chronic active EBV infection or de novo extranodal natural killer (NK)/T-cell lymphoma, nasal type?
New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.
Quintanilla-Martinez L, Swerdlow SH, Tousseyn T, Barrionuevo C, Nakamura S, Jaffe ES.
Virchows Arch. 2023 Jan;482(1):227-244. doi: 10.1007/s00428-022-03414-4. Epub 2022 Oct 11.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB.
Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.
EBV associated T- and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights.
Shafiee A, Shamsi S, Kohandel Gargari O, Beiky M, Allahkarami MM, Miyanaji AB, Aghajanian S, Mozhgani SH.
Rev Med Virol. 2022 Jul;32(4):e2328. doi: 10.1002/rmv.2328. Epub 2022 Feb 4.
Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
El-Mallawany NK, Curry CV, Allen CE.
Br J Haematol. 2022 Jan;196(1):31-44. doi: 10.1111/bjh.17638. Epub 2021 Jun 24.
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Bexte T, Alzubi J, Reindl LM, Wendel P, Schubert R, Salzmann-Manrique E, von Metzler I, Cathomen T, Ullrich E.
Oncoimmunology. 2022 May 31;11(1):2081415. doi: 10.1080/2162402X.2022.2081415. eCollection 2022.
How we treat chronic active Epstein-Barr virus infection.
Sawada A, Inoue M, Kawa K.
Int J Hematol. 2017 Apr;105(4):406-418. doi: 10.1007/s12185-017-2192-6. Epub 2017 Feb 16.
Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
Zambello R, Teramo A, Barilà G, Gattazzo C, Semenzato G.
Front Immunol. 2014 Feb 26;5:72. doi: 10.3389/fimmu.2014.00072. eCollection 2014.
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience.
Fei F, Stehr H, Zehnder JL.
Leuk Lymphoma. 2023 Sep;64(9):1536-1544. doi: 10.1080/10428194.2023.2220450. Epub 2023 Jun 17.
Chronic lymphoproliferative disorder of NK cells with TNFAIP3 and DNMT3A mutations.
Bulterys PL, Silva O.
Blood. 2021 Jun 17;137(24):3460. doi: 10.1182/blood.2021011812.
